Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Tim H Brummendorf, MD, Artur Gontarewicz, Gunhild Keller, Jürgen Moll, Melanie Braig, Imke Rohe, Edgar Jost, Oliver Galm, Carsten Bokemeyer, MD, Tessa Holyoake, Stefan Balabanov

Blood (2009) 114 (22): 1724.

https://doi.org/10.1182/blood.V114.22.1724.1724

Published: 2009

Journal Articles

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Stefan Balabanov, MD/PhD, Artur Gontarewicz, MD, Gunhild Keller, MD, Jürgen Moll, PhD, Carsten Bokemeyer, MD, Tessa L Holyoake, MD/PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 3227.

https://doi.org/10.1182/blood.V112.11.3227.3227

Published: 2008

Journal Articles

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Stefan Balabanov, MD/PhD, Thoma Wilhelm, PhD, Simone Venz, PhD, Christine Barret, Gunhild Keller, MD, Mirja Bernhardt, Artur Gontarewicz, MD, Melanie Braig, PhD, Reinhard Walther, PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 336.

https://doi.org/10.1182/blood.V112.11.336.336

Published: 2008

Journal Articles

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Artur Gontarewicz, Stefan Balabanov, Gunhild Keller, Riccardo Colombo, Alessio Graziano, Enrico Pesenti, Daniel Benten, Carsten Bokemeyer, Walter Fiedler, Jürgen Moll, Tim H. Brümmendorf

Blood (2008) 111 (8): 4355–4364.

https://doi.org/10.1182/blood-2007-09-113175

Published: 2008

Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.

Blood (2007) 110 (11): 1042.

https://doi.org/10.1182/blood.V110.11.1042.1042

Published: 2007

Journal Articles

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D, Gunhild Keller, M.D., Jens Panse, M.D., Mirja Bernhardt, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.

Blood (2007) 110 (11): 4568.

https://doi.org/10.1182/blood.V110.11.4568.4568

Published: 2007

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

NARROW

Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only